Analysts See $-0.05 EPS for IntelliPharmaCeutics International Inc. (IPCI)

March 14, 2018 - By Marguerite Chambers

 Analysts See $ 0.05 EPS for IntelliPharmaCeutics International Inc. (IPCI)

Analysts expect IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) to report $-0.05 EPS on April, 10.They anticipate $0.02 EPS change or 28.57 % from last quarter’s $-0.07 EPS. After having $-0.08 EPS previously, IntelliPharmaCeutics International Inc.’s analysts see -37.50 % EPS growth. The stock decreased 9.27% or $0.0573 during the last trading session, reaching $0.5606. About 562,884 shares traded or 56.33% up from the average. IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) has risen 16.57% since March 14, 2017 and is uptrending. It has underperformed by 0.13% the S&P500.

IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) Ratings Coverage

Among 2 analysts covering Intellipharmaceutics Intl (NASDAQ:IPCI), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Intellipharmaceutics Intl had 8 analyst reports since December 31, 2015 according to SRatingsIntel. The stock has “Buy” rating by Maxim Group on Tuesday, June 6. The firm has “Buy” rating given on Friday, July 21 by Maxim Group. The stock of IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) earned “Buy” rating by Maxim Group on Friday, June 30. H.C. Wainwright maintained it with “Buy” rating and $2.5 target in Monday, February 12 report. The stock of IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) earned “Buy” rating by Maxim Group on Thursday, December 31. The firm earned “Buy” rating on Monday, March 5 by H.C. Wainwright. The rating was downgraded by Maxim Group to “Hold” on Friday, February 16.

Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and makes novel and generic controlled-release and targeted-release oral solid dosage drugs in Canada. The company has market cap of $19.44 million. It develops various drug delivery systems and a pipeline of products based on its patented Hypermatrix technology in therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. It currently has negative earnings. The companyÂ’s lead product is Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for attention deficit hyperactivity disorders.

More notable recent IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) news were published by: which released: “Intellipharmaceutics International Inc.” on July 27, 2017, also with their article: “Intellipharmaceutics Announces US$4 Million Registered Direct Offering” published on October 11, 2017, published: “Intellipharmaceutics Announces Patent Litigation by Purdue against its Rexista …” on April 10, 2017. More interesting news about IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) were released by: and their article: “Intellipharmaceutics Announces Closing of US$4 Million Financing” published on October 13, 2017 as well as‘s news article titled: “Intellipharmaceutics Provides Operational Update” with publication date: January 24, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: